This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 4441299 results found since Jan 2013.

Peripheral nerve ultrasound changes in CIDP and correlations with nerve conduction velocity
Conclusions: US may, similar to MRI, have a supporting role in the diagnosis of CIDP. US and EDX changes are correlated.
Source: Neurology - February 23, 2015 Category: Neurology Authors: Di Pasquale, A., Morino, S., Loreti, S., Bucci, E., Vanacore, N., Antonini, G. Tags: Ultrasound, Chronic inflammatory demyelinating polyneuropathy, EMG ARTICLE Source Type: research

Spatiotemporal gait parameters as a potential outcome measure for CIDP (P7.338)
CONCLUSIONS: Gait parameters measured by GAITRite® walkway may detect changes following treatment with IVIG and correlate with changes in MRC sum score. Computerized gait assessment may be a useful outcome measure when used in combination with other validated clinical tools, particularly in patients with impaired gait.Disclosure: Dr. Chin has received personal compensation for activities with Grifols Bioscience as a consultant. Dr. Vo has received research support from Grifols. Dr. Carey has nothing to disclose. Dr. Langsdorf has nothing to disclose. Dr. Feuer has nothing to disclose. Dr. Latov has received personal co...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Chin, R., Vo, M., Carey, B., Langsdorf, J., Feuer, N., Latov, N. Tags: Practice, Policy, and Ethics Source Type: research

Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP
Conclusions A similarly high proportion of patients treated with IVIg or IVMP eventually relapse after therapy discontinuation but the median time to relapse was significantly longer after IVMP than IVIg. This difference may help to balance the more frequent response to IVIg than to IVMP in patients with CIDP.
Source: Journal of Neurology, Neurosurgery and Psychiatry - June 12, 2015 Category: Neurosurgery Authors: Nobile-Orazio, E., Cocito, D., Jann, S., Uncini, A., Messina, P., Antonini, G., Fazio, R., Gallia, F., Schenone, A., Francia, A., Pareyson, D., Santoro, L., Tamburin, S., Cavaletti, G., Giannini, F., Sabatelli, M., Beghi, E., for the IMC Trial Group, for Tags: Immunology (including allergy), Multiple sclerosis, Neuromuscular disease, Peripheral nerve disease Source Type: research

Transorbital sonography in CIDP patients: No evidence for optic nerve hypertrophy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an aquired, chronic progressive or relapsing immune mediated disorder of the peripheral nervous system. Thickening of optic nerve as a sign of cranial nerve involvement are increasingly reported in the last years. Our aim was to assess systematically for the first time the frequency of optic nerve hypertrophy in patients with CIDP by means of transorbital sonography (TOS).Thirty-four optic nerves of 17 patients with CIDP (age=60.8±13.3y, range=39-82y; 7 female) were examined by TOS.
Source: Journal of the Neurological Sciences - January 22, 2016 Category: Neurology Authors: Christos Krogias, Ilya Ayzenberg, Christoph Schroeder, Thomas Grüter, Ralf Gold, Min-Suk Yoon Source Type: research

Spatiotemporal Gait Changes Following IVIG Treatment for CIDP (P2.271)
Conclusion: Changes in STP were evident following treatment with IVIG and mirrored improvement in INCAT score, MRC, and grip strength. Objective gait assessment may be a useful outcome measure when used in combination with other validated tools.Disclosure: Dr. Vo has received personal compensation with Grifols. Dr. Chin has received personal compensation for activities with Grifols Bioscience as a consultant. Dr. Carey has nothing to disclose. Dr. Feuer has nothing to disclose. Dr. Miranda has nothing to disclose. Dr. Latov has received personal compensation for activities with Baxter, CSL Behring, Merck, Novartis, Xenopor...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Vo, M., Chin, R., Carey, B., Feuer, N., Miranda, C., Latov, N. Tags: Treatments of Peripheral Neuropathies and Cramps Source Type: research

Response to IVIG in Patients with CIDP: The INSIGHTS Quality Improvement Registry (P5.013)
Conclusions: Overall response rates to IVIG in patients diagnosed with demyelinating neuropathies are 48[percnt]. Adhering to AAN or EFNS criteria improved this response rate to 58[percnt] for CIDP and 63[percnt] for MMN. This represents the longest and largest collection of outcomes in patients receiving IVIG for neuromuscular diseases and suggests more specific recognition of diseases can improve outcomes and limit over-utilization.Disclosure: Dr Levine has received compensation from Lilly, Pfizer, Griffols, Baxter, Nufactor, Mallinckrodt, and Corinthian Reference Labs. Dr. Katz has received personal compensation for act...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Levine, T., Katz, J., Barohn, R., Saperstein, D., Wolfe, G., Katzin, L., Mozaffar, T., Dimachkie, M., Badger, G., Vaughn, L., Ritt, E., Greer, M. Tags: Neuromuscular Disease and Epilepsy ePoster Session Source Type: research

Hemoglobin Levels Improve Following Switch from Intravenous to Subcutaneous Administration of Immunoglobulin in CIDP and MMN (P5.044)
Conclusions: During switch from IVIG to SCIG there was a slight increase of hemoglobin levels with an improvement of parameters related to hemolytic activity. Study Support: Octapharma PharmaceuticalsDisclosure: Dr. Christiansen has nothing to disclose. Dr. Jakobsen has nothing to disclose. Dr. Markvardsen has received research support from Octapharma Pharmaceuticals.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Christiansen, I., Jakobsen, J., Markvardsen, L. Tags: Biomarkers and Clinical Features of Motor Neuron Disease and Biomarkers in Peripheral Nerve Disorders Source Type: research

Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?
Introduction Subcutaneous immunoglobulin (SCIg) has been recently proposed as an effective alternative to intravenous immunoglobulin (IVIg) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) treatment. The non-inferiority of SCIg over IVIg has been recently confirmed by a 4-month multicentre Italian observational study,1 where a similar efficacy was observed between the two therapies, with the SCIg showing possible advantages of stable plasmatic concentration2 and independence from hospital care. Here we report the 2-year experience of six Italian Neurological Centres...
Source: Journal of Neurology, Neurosurgery and Psychiatry - June 13, 2016 Category: Neurosurgery Authors: Cocito, D., Merola, A., Romagnolo, A., Peci, E., Toscano, A., Mazzeo, A., Gentile, L., Russo, M., Fazio, R., Filosto, M., Siciliano, G., Schirinzi, E., Nobile-Orazio, E., Lopiano, L. Tags: PostScript Source Type: research

A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients
Conclusion: This study shows that HIV-infected patients with CIDP were younger, were more often female, displayed a monophasic progressive course, were highly steroid-responsive, and went into remission within 12 months of corticosteroid initiation.
Source: Neurology Neuroimmunology and Neuroinflammation - December 14, 2016 Category: Neurology Authors: Moodley, K., Bill, P. L. A., Patel, V. B. Tags: HIV, Peripheral neuropathy Article Source Type: research

Changes in Spatiotemporal Gait Parameters Following IVIG Treatment for CIDP
Conclusion: Assessment of gait parameters, in particular velocity, step phase and swing phase, is a potentially sensitive outcome measure for evaluating treatment response in CIDP. This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - December 31, 2016 Category: Internal Medicine Authors: Mary L. Vo, Russell L. Chin, Caroline Miranda, Norman Latov Tags: Research Article Source Type: research

Resistance and aerobic training improve muscle strength and aerobic capacity in CIDP
This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - March 27, 2017 Category: Internal Medicine Authors: Lars H. Markvardsen, Kristian Overgaard, Karen Heje, S øren H. Sindrup, Ingelise Christiansen, John Vissing, Henning Andersen Tags: Research Article Source Type: research

P1-06. Two CIDP patients with anti-CNTN1 IgG4 antibodies and nephrotic syndrome
Previous studies showed that CIDP patients with anti-CNTN1 IgG4 antibodies form a specific subtype, which shows subacute progression and poor prognosis. In contrast, nephropathy has been recognized as a rare complication in CIDP and other immune-mediated neuropathies. We here describe two CIDP patients with anti-CNTN1 IgG4 antibodies and nephrotic syndrome. The patients were 35- (P1) and 69-year-old (P2) males. Both patients developed subacute course of sensory and motor neuropathy. In parallel with neuropathy course, nephrotic syndrome was present.
Source: Clinical Neurophysiology - August 17, 2017 Category: Neuroscience Authors: Norito Kokubun, Takahide Nagashima, Kei Funakoshi, Tomoko Komagamine, Koichi Hirata, Nobuhiro Yuki Source Type: research

Severe refractory CIDP: a case series of 10 patients treated with bortezomib
AbstractTreatment options for patients with aggressive chronic inflammatory demyelinating neuropathy are limited and include the anti-CD20 antibody rituximab and the immunosuppressive regime cyclophosphamide. We aimed to investigate retrospectively the efficacy of bortezomib, a proteasome inhibitor tackling highly metabolically active cell types such as plasma cells, in a case series of 10 treatment refractory CIDP patients. All patients reported showed a deterioration of the clinical CIDP scores under first-line treatment or escalating treatment with cyclophosphamide or rituximab. One or two cycles of bortezomib treatment...
Source: Journal of Neurology - August 23, 2017 Category: Neurology Source Type: research

P 26 Evaluation of clinical, electrophysiological, sonographic and MRI characteristics of the CIDP spectrum disorder
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease with a wide spectrum of clinical presentation and treatment response. Electrophysiological studies constitute the gold standard used to characterise CIDP patients and contribute to treatment decisions. However, mostly at late stages electrophysiological methods show a pronounced axonal damage and are not able to distinguish CIDP subtypes. Therefore, therapeutic decisions have to be based solely on the clinical course.
Source: Clinical Neurophysiology - September 8, 2017 Category: Neuroscience Authors: K. Pitarokoili, M. Kronlage, P. B äumer, A. Kerasnoudis, R. Gold, M. Bendszus, M.S. Yoon Tags: Poster Source Type: research

Electrodiagnostic errors contribute to CIDP misdiagnosis
This article is protected by copyright. All rights reserved.
Source: Muscle and Nerve - October 20, 2017 Category: Internal Medicine Authors: Jeffrey A Allen, John Ney, Richard A Lewis Tags: Clinical Research Article Source Type: research